How to select amongst available options for the treatment of advanced RCC?

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Escudier, B ^a   Albiges, L ^a   Massard, C ^a   Loriot, Y ^a   Fizazi, K ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Antiangiogenic; MTOR inhibitor; Renal cell carcinoma; Sequential therapy; TKI

Indexed keywords

AXITINIB; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERFERON; PAZOPANIB; PROTEIN KINASE B; PROTEIN S6; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR MARKER; VASCULOTROPIN;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CLINICAL DECISION MAKING; CYTOREDUCTIVE SURGERY; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME PHOSPHORYLATION; HISTOLOGY; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; NEPHRECTOMY; PATIENT COMPLIANCE; PATIENT PREFERENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR;

EID: 84866766405     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds352     Document Type: Article

References (18)

1. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125-134.
2. Motzer R, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2): 115-124.
3. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356(22): 2271-2281.
4. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
5. Motzer RJ, Escudier B, Oudard S et al. Everolimus for advanced renal cell carcinoma. Lancet 2008; 372(9637): 449-456.
6. Sternberg C, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
7. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378(9807): 1931-1939.
8. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22(3): 454-463.
9. Manola J, Royston P, Elson P et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working Group. Clin Cancer Res 2011; 17: 5443-5450.
10. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27(34): 5794-5799.
11. Negrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the groupe français d'immunotherapie. Ann Oncol 2002; 13: 1460-1468.
12. Negrier S, Gravis G, Pérol D et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011; 12(7): 673-680.
13. Patard JJ, Leray E, Rioux-Leclercq N et al. Prognostic value of histologic subtypes in renal cell carcinomas: a multicenter experience. J Clin Oncol 2005; 23: 2763-2771.
14. Malouf GG, Camparo P, Molinie V et al. Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol 2011; 185(1): 24-29.
15. Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171: 1071-1076.
16. Escudier B, Porta C, Bono P et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo controlled, cross-over study in pts with metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting. Abstract CRA4502. Presented June 2, 2012.
17. Escudier B, Szczylik C, Porta C et al. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol 2012; 9(6): 327-337.
18. Atkins MB, Choueri T, Cho D et al. Treatment selection for patients with metastatic renal cell carcinoma. Cancer 2009; 115 (10 Suppl): 2327-2333.